“Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 2 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s446, https://doi.org/10.25251/skin.8.supp.446.